乐脂平对Ⅱ型糖尿病血脂代谢的临床研究

Clinicl Study with Acipimox in Type II Diabetic Patients with Lipopro-teinaemia Metabolism

对32例Ⅱ型糖尿病伴高脂血症患者，日服乐脂平500mg，4～12周后，血TC(总胆因醇)下降9.28％～11.23％。血TG(甘油三脂)下降13．02％～34.62％．血糖和胰岛素水平无明显增加。脂蛋白电泳结果显示：HDL在服药4～12周后明显增加。VLDL和LDL明显减少。血糖、胰岛素与血TC和TG相互之间无明显相关性、治疗中未见明显副作用；表明乐脂平具有较好的阵低血脂和升高HDL的作用。且无血糖和胰岛素水平的增加．是一种较理想的治疗糖尿痛高脂血症的药物。

Thirty-two NIDDL patients with concomitant hyperlipoproteinaemia were administrated a dose of 500mg acipimox daily. After 4-12 weeks treatment, the serum TC fell by 9,28 % to 11.23 % whereas a 13.62 % to 34.62 % . reduction in TC was found. The serum glucose and insulin levels were not significantly increased. The lipoprotein electrophoresis showed that HDL was significantly raised while VLDL and LDL were markedly reduced after 4-12 week treatment. There was no obvious relationship between serum glucose, insulin and TC, TG. No marked side-effect was recorded during the treatment. The result indicated that acipimox had a better effect on reducing serum lipid level and on increasing HDL level and was a satisfactory lipid - lowering agent in diabetic patients with hyperlipoproteinaemia.